Every 10-Q that Larimar Therapeutics, Inc. (LRMR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LRMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LRMR filings page.
Larimar Therapeutics, Inc. reported a net loss of $32.8 million for the quarter and $62.4 million for the first half of 2026 as it increased investment in nomlabofusp, its lead therapy for Friedreich's ataxia. Quarterly operating expenses rose to $34.4 million, mainly from higher R&D and commercial readiness spending.
Cash, cash equivalents and marketable securities of $156.3 million as of June 30, 2026 are expected to fund operations into the third quarter of 2027; however, management concluded these resources will not cover at least 12 months of planned operations from the reporting date and raised substantial doubt about its ability to continue as a going concern, indicating a need for additional capital.
Nomlabofusp advanced meaningfully: it received FDA Breakthrough Therapy Designation, was selected for the FDA’s START pilot program, and moved into a rolling BLA with the first module submitted in June 2026. Open-label data in 43 patients showed sustained increases in frataxin and directional improvements versus natural history, though 10 participants experienced anaphylaxis and discontinued. A global Phase 3 confirmatory trial is planned to begin dosing in the third quarter of 2026.
Larimar Therapeutics reported a net loss of $29.6 million for the quarter ended March 31 2026, similar to the prior year’s $29.3 million, as it continues to invest heavily in developing nomlabofusp for Friedreich’s ataxia.
Research and development expenses were $25.0 million and general and administrative costs were $6.1 million. Cash, cash equivalents and marketable securities rose to $200.4 million, helped by a February underwritten equity offering that generated net proceeds of about $107.6 million.
Larimar ended the quarter with an accumulated deficit of $464.4 million but believes its current cash can fund operations for at least twelve months. The FDA granted Breakthrough Therapy Designation to nomlabofusp, and the company plans a rolling BLA starting in June 2026, targeting a potential U.S. launch in the first half of 2027 if approved.
Larimar Therapeutics (LRMR) reported Q3 2025 results highlighted by increased R&D investment as it advances nomlabofusp for Friedreich’s ataxia. The company posted a net loss of $47.7 million, driven by research and development expense of $44.9 million and general and administrative expense of $4.6 million. Cash, cash equivalents and marketable securities totaled $175.4 million as of September 30, 2025, supported by $65.0 million of net proceeds from a July 31 underwritten offering.
Management reiterated its regulatory path: participation in FDA’s START pilot, FDA feedback that skin frataxin (FXN) concentration may be considered a reasonably likely surrogate endpoint subject to future review, and BLA safety database parameters. The company targets a BLA submission for accelerated approval in Q2 2026 and plans a regulatory and study status update in Q1 2026. In its open-label study, 65 participants have received at least one dose, with directional improvements across clinical outcomes and FXN levels; 7 anaphylaxis events occurred early in dosing and the firm is implementing a modified starting regimen agreed with FDA. Shares outstanding were 85,590,392 as of November 3, 2025.
Larimar Therapeutics (LRMR) is advancing nomlabofusp through clinical development with multiple recent regulatory and clinical milestones. The company increased open-label dosing to 50 mg daily and has active participants receiving that dose. In March 2025 the Safety Monitoring Team deemed anaphylaxis a likely adverse drug reaction and the protocol was amended to add antihistamine premedication for the first month. Adolescent PK run-in dosing (ages 12–17) completed dosing of 14 participants in March 2025 and some adolescents are transitioning into the open-label study.
Regulatory interactions include FDA acceptance of a lyophilized formulation for clinical use and FDA feedback under the START pilot that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint, subject to review in a future marketing application. FDA recommended safety database targets for an accelerated BLA: at least 30 participants with six months continuous exposure and a subset of at least 10 with one year. Larimar plans a BLA submission in Q2 2026. A July 2025 publication reported supporting nonclinical data. The company raised net proceeds of approximately $65.1 million in July 2025, which management expects to fund operations into Q4 2026.